Olga Rivero-Menendez

Olga Rivero-Menendez

Auto-generated profile, based on publicly available information

Olga Rivero-Menendez

Medical Mycology Reference Laboratory, National Center for Microbiology, Instituto de Salud Carlos III, Madrid, Spain

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 July 2016 in Journal of Fungi
Verified
Journal Article
Open access
PDF file
OROlga Rivero-Menendez
Olga Rivero-Menendez
Ana Alastruey-IzquierdoAna Alastruey-Izquierdo
Ana Alastruey-Izquierdo
EMEmilia Mellado
Emilia Mellado
MCManuel Cuenca-Estrella
Manuel Cuenca-Estrella
Since the first description of an azole-resistant A. fumigatus strain in 1997, there has been an increasing number of papers describing the emergence of azole resistance. Firstly reported in the USA and soon after in Europe, it has now been described worldwide, challenging the management of human aspergillosis. The main mechanism of resistance is the modification of the azole target enzyme: 14-α sterol demethylase, encoded by the cyp51A gene; although recently, other resistance mechanisms have also been implicated. In addition, a shift in the epidemiology has been noted with other Aspergillus species (mostly azole resistant) increasingly being reported as causative agents of human disease. This paper reviews the current situation of Aspergillus azole resistance and its implications in the clinical setting.

19 March 2019 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Open access
PDF file
OROlga Rivero-Menendez
Olga Rivero-Menendez
MCManuel Cuenca-Estrella
Manuel Cuenca-Estrella
Ana Alastruey-IzquierdoAna Alastruey-Izquierdo
Ana Alastruey-Izquierdo
To investigate the in vitro activity of olorofim (F901318), a novel broad-spectrum antifungal agent, against 150 strains belonging to 16 different cryptic species of Aspergillus by EUCAST and CLSI methodologies. Olorofim, amphotericin B, micafungin, posaconazole and voriconazole were tested against cryptic species belonging to Aspergillus fumigatus complex (n = 57), Aspergillus ustus complex (n = 25), Aspergillus niger complex (n = 20), Aspergillus flavus complex (n = 20), Aspergillus circumdati complex (n = 15) and Aspergillus terreus complex (n = 13) using EUCAST and CLSI methodologies for broth microdilution susceptibility testing of antifungal agents. Olorofim was the only drug with activity against all cryptic species of Aspergillus tested, including the multiresistant species Aspergillus lentulus, Aspergillus fumigatiaffinis and Aspergillus calidoustus. Geometric means of MICs for olorofim were lower (0.017, 0.015 and 0.098 mg/L, respectively, for EUCAST; and 0.015, 0.015 and 0.048 mg/L, respectively, for CLSI) than for amphotericin B (4.438, 12.699 and 0.554 mg/L, respectively, for EUCAST; and 0.758, 1.320 and 0.447 mg/L, respectively, for CLSI), voriconazole (2.549, 2.297 and 5.856 mg/L, respectively, for EUCAST; and 2.071, 1.741 and 5.657 mg/L, respectively, for CLSI) and posaconazole (0.307, 0.308 and 12.996 mg/L, respectively, for EUCAST; and 0.391, 0.215 and 9.514 mg/L, respectively, for CLSI). Olorofim shows encouraging in vitro activity against cryptic species of Aspergillus that can be hard to treat with current antifungal therapies. Further studies are warranted in order to assess its efficacy.

1 November 2015 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
PDF file
AFA. Forastiero
A. Forastiero
VGV. Garcia-Gil
V. Garcia-Gil
ORO. Rivero-Menendez
O. Rivero-Menendez
RGR. Garcia-Rubio
R. Garcia-Rubio
MMM. C. Monteiro
M. C. Monteiro
EMEmilia Mellado
Emilia Mellado
In invasive candidiasis, there has been an epidemiological shift from Candida albicans to non- albicans species infections, including infections with C. glabrata , C. parapsilosis , C. tropicalis , and C. krusei . Although the prevalence of C. krusei remains low among yeast infections, its intrinsic resistance to fluconazole raises epidemiological and therapeutic concerns. Echinocandins have in vitro activity against most Candida spp. and are the first-line agents in the treatment of candidemia. Although resistance to echinocandin drugs is still rare, individual cases of C. krusei resistance have been reported in recent years, especially with strains that have been under selective pressure. A total of 15 C. krusei strains, isolated from the blood, urine, and soft tissue of an acute lymphocytic leukemia patient, were analyzed. Strains developed echinocandin resistance during 10 days of caspofungin therapy. The molecular epidemiology of the isolates was investigated using two different typing methods: PCR-based amplification of the species-specific repetitive polymorphic CKRS-1 sequence and multilocus sequence typing. All isolates were genetically related, and the mechanism involved in decreased echinocandin susceptibility was characterized. Clinical resistance was associated with an increase in echinocandin MICs in vitro and was related to three different mutations in hot spot 1 of the target enzyme Fks1p. Molecular evidence of the rapid acquisition of resistance by different mutations in FKS1 highlights the need to monitor the development of resistance in C. krusei infections treated with echinocandin drugs.

6 February 2019 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Closed access
OROlga Rivero-Menendez
Olga Rivero-Menendez
MCManuel Cuenca-Estrella
Manuel Cuenca-Estrella
AAAna Alastruey-Izquierdo
Ana Alastruey-Izquierdo
APX001A (E1210) is a novel broad-spectrum antifungal agent that inhibits Gwt1p, a protein that plays an important role in fungal cell wall integrity. Previous studies have shown that APX001A has broad activity against most species of Candida, Aspergillus, Scedosporium, Fusarium and Mucorales. To investigate the in vitro activity of APX001A against 200 isolates belonging to 20 different species of Fusarium, Scedosporium, Lomentospora, Alternaria, cryptic species of Aspergillus and Mucorales. APX001A and comparators were tested using EUCAST and CLSI methodologies for broth microdilution susceptibility testing of antifungal agents. APX001A was generally inactive against Mucorales, but active against all cryptic species of Aspergillus and Scedosporium/Lomentospora species. APX001A shows encouraging in vitro activity against some emerging fungi that are hard to treat with currently available antifungals.

1 September 2018 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
PDF file
Ana Alastruey-IzquierdoAna Alastruey-Izquierdo
Ana Alastruey-Izquierdo
LALaura Alcazar-Fuoli
Laura Alcazar-Fuoli
OROlga Rivero-Menéndez
Olga Rivero-Menéndez
JAJosefina Ayats
Josefina Ayats
CCCarmen Castro
Carmen Castro
MCManuel Cuenca-Estrella
Manuel Cuenca-Estrella
Antifungal resistance is increasing by the emergence of intrinsically resistant species and by the development of secondary resistance in susceptible species. A previous study performed in Spain revealed levels of azole resistance in molds between 10 to 12.7% but secondary resistance in A. fumigatus was not detected. We used itraconazole supplemented media to select resistant strains. A total of 500 plates supplemented with 2 mg/L of ITZ were sent to 10 Spanish tertiary hospitals, molecular identification and antifungal susceptibility testing were performed. In addition, cyp51A gene was sequenced in those A. fumigatus strains showing azole resistance. A total of 493 isolates were included in the study. Sixteen strains were isolated from patients with an infection classified as proven, 104 as probable and 373 as colonization. Aspergillus was the most frequent genera isolated with 80.3% followed by Scedosporium/Lomentospora (7.9%), Penicillium/Talaromyces (4.5%), Fusarium (2.6 %) and the order Mucorales (1 %). Antifungal resistance was detected in Scedosporium/Lomentospora species, Fusarium, Talaromyces and Mucorales. Three strains of A. fumigatus senso stricto were resistant to azoles, two of them harbored TR34+L98H mechanism of resistance and the other one had no mutations in cyp51A. The level of azole resistance in A. fumigatus remains low but cryptic species represent over 10% of the isolates and have broader but overall higher range of antifungal resistance

11 July 2019 in Frontiers in Microbiology
Verified
Journal Article
Open access
OROlga Rivero-Menendez
Olga Rivero-Menendez
PNPatricia Navarro-Rodriguez
Patricia Navarro-Rodriguez
LBLeticia Bernal-Martinez
Leticia Bernal-Martinez
GMGema Martin-Cano
Gema Martin-Cano
LLLaura Lopez-Perez
Laura Lopez-Perez
Ana Alastruey-IzquierdoAna Alastruey-Izquierdo
Ana Alastruey-Izquierdo
The pathogenic yeast Candida glabrata has become a public health issue due to the increasing number of echinocandin resistant clinical strains reported. In this study, acquisition and development of resistance to this antifungal class were studied in serial C. glabrata isolates from five patients admitted in two Spanish hospitals with a resistant profile against echinocandins associated with different mutations in hot-spot 1 of FKS2 gene. For two of these patients susceptible FKS wild-type isolates obtained prior to resistant ones were also investigated. Isolates were genotyped using multilocus sequence typing and microsatellite length polymorphism techniques, which yielded comparable results. Susceptible and resistant isolates from the same patient had the same genotype, being sequence type (ST) 3 the most prevalent among them. Isolates with different FKS mutations but the same ST were present in the same patient. MSH2 gene alterations were also studied to investigate their correlation with antifungal resistance acquisition but no association was found with antifungal resistance nor with specific genotypes. In vitro exposure to increasing concentrations of micafungin to susceptible isolates developed colonies carrying FKS mutations in agar plates containing a minimum concentration of 0.06 mg/L of micafungin after less than 48 h of exposure. We investigated the correlation between development of resistance and genotype in a set of susceptible strains after being in vitro exposed to micafungin and anidulafungin but no correlation was found. Mutant prevention concentration values and spontaneous growth frequencies after selection with both echinocandins were statistically similar, although FKS mutant colonies were more abundant after micafungin exposure (p < 0.001). Mutation S663P and F659 deletion were the most common ones found after selection with both echinocandins.